Effects of Nefazodone on Treatment of Female Cocaine Abusers - 3

This study has been completed.

First Received: September 20, 1999 Last Updated: August 16, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	University of Minnesota
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000286

Purpose

The purpose of this study is to determine the effects of nefazedone on cocaine self-administration in depressed and non-depressed female cocaine users.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Nefazodone	Phase II

Study Type:	Interventional
Study Design:	Treatment, Double-Blind, Placebo Control
Official Title:	Effects of Nefazodone on Treatment of Female Cocaine Abusers

Resource links provided by NLM:

MedlinePlus related topics: Depression

Drug Information available for: Nefazodone hydrochloride Nefazodone

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Craving
Drug use
Depression
Life functioning
HIV risk behaviors

Estimated Enrollment:	0
Study Start Date:	December 1996
Estimated Study Completion Date:	December 2001

Detailed Description:

This study evaluated the effect of nefazodone on reducing cocaine use and craving in both depressed and nondepressed women and if there was a greater effect in depressed women.

Eligibility

Ages Eligible for Study:	18 Years to 55 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Females, ages 18-55, minimum use of 8 days of the last 30, minimum of 8th grade education, current diagnosis of cocaine abuse/dependence

Exclusion Criteria:

Unstable medical illness, dx of MR, OBS, bipolar

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000286

Locations

United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Minnesota

Investigators

Principal Investigator:

Dorothy Hatsukami, Ph.D.

University of Minnesota

More Information

No publications provided

Study ID Numbers:	NIDA-09259-3, P50-09259-3
Study First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000286 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Nefazodone
Mental Disorders
Therapeutic Uses
Psychotropic Drugs
Substance-Related Disorders

Disorders of Environmental Origin
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Pharmacologic Actions
Antidepressive Agents

ClinicalTrials.gov processed this record on November 27, 2009